Liquidia Corporation (LQDA)
NASDAQ: LQDA
· Real-Time Price · USD
14.01
0.04 (0.29%)
At close: May 01, 2025, 3:59 PM
14.60
4.25%
After-hours: May 01, 2025, 07:05 PM EDT
Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
It also distributes generic treprostinil injection in the United States.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation
| Country | United States |
| IPO Date | Jul 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Dr. Roger A. Jeffs Ph.D. |
Contact Details
Address: 419 Davis Drive Morrisville, North Carolina United States | |
| Website | https://www.liquidia.com |
Stock Details
| Ticker Symbol | LQDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819576 |
| CUSIP Number | 53635D202 |
| ISIN Number | US53635D2027 |
| Employer ID | 85-1710962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Roger A. Jeffs Ph.D. | Chief Executive Officer & Director |
| Michael Kaseta | Chief Operating Officer & Chief Financial Officer |
| Russell Schundler | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 4 | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 23, 2025 | 4 | Filing |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |